Delfictus I/O builds physics-grounded computational systems for therapeutic discovery and molecular design. The platform and its underlying methods are proprietary and under active development. Substantive materials are shared confidentially with qualified research, clinical, and commercial partners.
Characterize therapeutically relevant sites across difficult protein targets that conventional structure-based methods overlook.
Generate and prioritize novel chemical matter against validated targets, with provenance retained end to end.
Methods evaluated under blinded, reproducible protocols — engineered for cleanroom and compliance-grade deployment.
Methodology, results, and platform access are disclosed exclusively to parties operating under an executed CDA / NDA. Begin a request below, or verify a key already issued to you.
Introduce yourself and your interest. Qualified inquiries receive a confidentiality agreement and a scoped briefing.
Research@delfictus.comWe respond to qualified inquiries individually. No confidential material is exchanged before an agreement is in place.
Issued a key under agreement? Verify it to confirm your provisioning. Keys are single-purpose and tied to your engagement.
Verification is logged. Don't have a key? Request access.